Vamorolone treatment improves skeletal muscle outcome in a critical illness myopathy rat model

Abstract

These results show that vamorolone provides a GC intervention superior to typical GCs in improving CIM outcomes. Further, the findings do not support the notion that moderate-dose GC treatment represents a factor triggering CIM.